Academic Bibliography

 Search 200 years of publications by Ghent University researchers.
Advanced search
1 file | 611.82 KB
Add to list
  1. Search results
  2. Chemotherapy at the wheel of ALL relapse

Chemotherapy at the wheel of ALL relapse

Julie Morscio (UGent) and Pieter Van Vlierberghe (UGent)
(2020) BLOOD. 135(1). p.3-5
Author
Organization
Abstract
In this issue of Blood, Li et al(1) present an extensive in-depth genetic characterization of diagnostic, relapse, and remission samples from a cohort of 103 pediatric patients with acute lymphoblastic leukemia (ALL) treated according to the Shanghai Children's Medical Center ALL-2005 frontline protocol. Together with data obtained from 208 serial bone marrow samples collected during ALL therapy, their work suggests that relapse in a fraction of childhood ALL patients is driven by chemotherapy-induced mutations, which impact therapy response.
Keywords
T-CELL, RESISTANCE

Downloads

  • Download
    (...).pdf
    • full text (Published version)
    • |
    • UGent only
    • |
    • PDF
    • |
    • 611.82 KB

Citation

Please use this url to cite or link to this publication:

MLA
Morscio, Julie, and Pieter Van Vlierberghe. “Chemotherapy at the Wheel of ALL Relapse.” BLOOD, vol. 135, no. 1, 2020, pp. 3–5, doi:10.1182/blood.2019003870.
APA
Morscio, J., & Van Vlierberghe, P. (2020). Chemotherapy at the wheel of ALL relapse. https://doi.org/10.1182/blood.2019003870
Chicago author-date
Morscio, Julie, and Pieter Van Vlierberghe. 2020. “Chemotherapy at the Wheel of ALL Relapse.” BLOOD. https://doi.org/10.1182/blood.2019003870.
Chicago author-date (all authors)
Morscio, Julie, and Pieter Van Vlierberghe. 2020. “Chemotherapy at the Wheel of ALL Relapse.” BLOOD. doi:10.1182/blood.2019003870.
Vancouver
1.
Morscio J, Van Vlierberghe P. Chemotherapy at the wheel of ALL relapse. Vol. 135, BLOOD. 2020. p. 3–5.
IEEE
[1]
J. Morscio and P. Van Vlierberghe, “Chemotherapy at the wheel of ALL relapse,” BLOOD, vol. 135, no. 1. pp. 3–5, 2020.
@misc{8665841,
  abstract     = {{In this issue of Blood, Li et al(1) present an extensive in-depth genetic characterization of diagnostic, relapse, and remission samples from a cohort of 103 pediatric patients with acute lymphoblastic leukemia (ALL) treated according to the Shanghai Children's Medical Center ALL-2005 frontline protocol. Together with data obtained from 208 serial bone marrow samples collected during ALL therapy, their work suggests that relapse in a fraction of childhood ALL patients is driven by chemotherapy-induced mutations, which impact therapy response.}},
  author       = {{Morscio, Julie and Van Vlierberghe, Pieter}},
  issn         = {{0006-4971}},
  keywords     = {{T-CELL,RESISTANCE}},
  language     = {{eng}},
  number       = {{1}},
  pages        = {{3--5}},
  series       = {{BLOOD}},
  title        = {{Chemotherapy at the wheel of ALL relapse}},
  url          = {{http://dx.doi.org/10.1182/blood.2019003870}},
  volume       = {{135}},
  year         = {{2020}},
}
Altmetric
View in Altmetric
Web of Science
Times cited: